lactitol | 148346-85-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: lactitol
• 英文别名: 4-O-alpha-d-galactopyranosyl-d-sorbitol；(2S,3R,4R,5R)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,5,6-pentol
• CAS: 148346-85-4
• 化学式: C₁₂H₂₄O₁₁
• 分子量: 344.316
• InChiKey: VQHSOMBJVWLPSR-AVXCFOOMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.2
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  201
• 氢给体数：
  9
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  lactitol 、 (5-cholesten-yl) vinyl decanedioate 在 Novozym 435 lipase 作用下， 以 吡啶 、 丙酮 为溶剂， 反应 31.1h， 以94.3%的产率得到(5-cholesten-3β-yl) [(4-O-β-D-galactopyranosyl)D-glucitol-6]sebacate
  参考文献：
  名称：

  Lipase-catalyzed synthesis of novel galactosylated cholesterol

  摘要：

  In an organic phase system, an enzymes lipase was used as a catalyst to synthesize galactosylated cholesterol, (5-cholesten-3b-yl)[(4-O-beta-D-galactopyranosyl)D-glucitol-6] sebacate (CHS-SE-LA), which contains galactose residues. Its chemical structure was characterized by ESI-MS, and NMR. For HepG2 cells, the cellular fluorescence intensities of liposomes modified with CHS-SE-LA (GAL-FL) were as much as 2.6-fold (p < 0.01) control liposomes (FL). Moreover, the presence of excess galactose significantly inhibited the uptake of GAL-FL suggesting ASGPR mediated uptake. In conclusion, the novel galactosylated ligand CHS-SE-LA was synthesized by lipase-catalyzation and revealed a great potential as drug carrier materials for hepatocyte-selective targeting. (C) 2015 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.cclet.2015.01.005

文献信息

• Prebiotic oral care methods using a saccharide
  申请人：COLGATE-PALMOLIVE COMPANY

  公开号：US10328010B2

  公开（公告）日：2019-06-25

  The disclosure relates to methods of enhancing beneficial oral bacteria and decreasing harmful oral bacteria comprising administering oral care compositions comprising a saccharide prebiotic, e.g., selected from D-turanose, D-melezitose, D-lactitol, myoinositol, and N-acetyl-D-mannosamine; and oral care compositions for use in such methods. The disclosure also relates to methods of using prebiotic oral care compositions, methods of screening, and methods of manufacture.

  本公开涉及增强有益口腔细菌和减少有害口腔细菌的方法，包括施用包含糖类益生元的口腔护理组合物，例如，选自D-吐兰糖、D-麦芽糖、D-乳糖醇、肌醇和N-乙酰-D-甘露糖胺；以及用于此类方法的口腔护理组合物。本公开还涉及使用益生元口腔护理组合物的方法、筛选方法和制造方法。
• Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
  申请人：Klele Luke

  公开号：US10624939B2

  公开（公告）日：2020-04-21

  Disclosed herein are natural product compositions for treating ADHD and related disorders.

  本文公开了用于治疗多动症及相关疾病的天然产品组合物。
• 10.3109/10242422.2015.1053469
  作者：Nie, Hua、Zheng, Pin-Jing、Luo, Li-Hua、Cheng, Yi

  DOI：10.3109/10242422.2015.1053469

  日期：——
• EP2761000B1
  申请人：——

  公开号：EP2761000B1

  公开（公告）日：2016-03-16
• STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS
  申请人：Qiagen GmbH

  公开号：EP2761020B1

  公开（公告）日：2018-06-13